The current state of immunotherapy for gliomas: an eye toward the future
Open Access
- 1 September 2019
- journal article
- review article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 131 (3) , 657-666
Abstract
The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.Keywords
This publication has 67 references indexed in Scilit:
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trialNature, 2018
- Actively personalized vaccination trial for newly diagnosed glioblastomaNature, 2018
- Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaJournal of Clinical Oncology, 2018
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive GlioblastomaJAMA Oncology, 2017
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escapeJournal of Clinical Investigation, 2016
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastomaScience Translational Medicine, 2015
- Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade gliomaJournal of Neuro-Oncology, 2007
- Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new viewImmunology Today, 1992
- Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissueJournal of Neurosurgery, 1981
- DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORSJournal of Experimental Medicine, 1972